Clinical Trial Update: Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CASAD (calcium aluminosilicate anti-diarrheal) for Clostridium difficile infection was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• CASAD (Calcium Aluminosilicate Anti-Diarrheal) (Calcium aluminosilicate anti-diarrheal)

Snippet

Sponsor: Salient Pharmaceuticals Incorporated | Conditions: Diarrhoea, Clostridium Difficile | Phase 2 | Status: TERMINATED | Results posted: 2013-03-08